Temenos Launches SaaS Explainable AI Models to Help Banks Support Small Businesses and Retail Customers During COVID-19 Crisis
23.4.2020 09:30:00 EEST | Business Wire | Press release
Temenos (SIX: TEMN), the banking software company, announced today the launch of Explainable AI (XAI) models to enable banks and credit unions to rapidly offer loans to small and medium enterprises (SMEs) that have seen their cash flow disrupted by the COVID-19 outbreak. These patented XAI models allow banks to accelerate digital onboarding, conduct eligibility checks and process loan applications for SMEs and retail customers. The models are available as part of the Temenos AI portfolio or can be integrated with Temenos Infinity, the leading digital omnichannel product, and are delivered as Temenos SaaS for fast and scalable deployment.
Max Chuard, Chief Executive Officer, Temenos, said: “These are challenging times for small businesses in particular. As the leader in banking software, Temenos is committed to innovation that not only keeps banks and the global economy running, but also helps SMEs and retail customers access funding at a time of financial distress. We are delivering our cloud-native, advanced AI banking software as SaaS to enable banks qualify and process loans rapidly. I am proud that with our technology we can provide banks with a modern digital banking platform and decision-making capabilities, allowing them to move incredibly fast and compress projects that would usually take months into days.”
Temenos’ XAI models help banks make urgent lending decisions that are transparent and explainable in human language to the end-users, customers and the regulators. These models enable banks to identify appropriate products that carry an acceptable level of risk for both the customer and the bank. The SME model, in particular, provides on average over 25% greater accuracy compared to the risk score provided by leading credit bureaus, allowing banks to increase their pass rate by 20% while keeping defaults under control.
The new XAI models enable banks to take into account a wide range of variables when making lending decisions, such as additional incomes, new cost reductions, and alternative forms of collateral. Temenos XAI models can instantly calculate the impact of new variables and suggest additional terms and conditions.
As a result of the pandemic, banks are being asked to lend in unusual circumstances, requiring them to manage the twin pressures of increasing arrears and political pressure not to trigger defaults. Government Initiatives like the UK Coronavirus Business Interruption Loan Scheme (CBILS) and the US Paycheck Protection Program (PPP) are aiming to help SMEs in need of financial support by promoting emergency bank loans.
Jerry Silva, Research Vice President, IDC, said: “A record number of small businesses and individuals are now applying for loans and financial relief. In the face of this demand, banks need to respond by providing digital self-service user journeys, quickly conducting eligibility checks, adhering to bank risk criteria, and establishing appropriate pricing. Solutions like Temenos’ new XAI models are designed to help banks accelerate the loan application process by centralizing and enforcing policy rules using AI to ensure decisions are based on bank-specified criteria while maintaining transparency with customers and maintaining compliance and risk controls.”
These API-driven XAI models can be rolled out with the associated policy rules, allowing smart decision-making with minimal integration that can be deployed in the cloud in days or just a few weeks. This consistency in decision-making helps frontline staff by reducing the need for manual intervention, which can slow the processing of the huge volumes of applications being considered. Temenos’ XAI models can be used by any business user with minimum reliance on the IT department.
The XAI models available worldwide include:
- Temenos AI – SME Smart Decisioning: Temenos provides centrally created support for decision makers at the front line, for on-boarding, edibility checks and rapid loan processing. Furthermore, it reduces the need for human intervention in underwriting departments. The model is already proven with blue-chip UK lenders and can rapidly augment the decision-making processes already in place.
- Temenos AI – Urgent Relief Loan: Identify customers with a significant drop in income, who are at financial risk and offer further credit or credit deferral products.
- Temenos AI – Personalization: Offer personalized products to customers in real-time based on their changing behaviors and needs identified using Explainable AI models
- Temenos AI – Loan Pre-Approvals: Lending pre-approval for all customers. Expedite short- term urgent lending to the greatest number of customers.
- Temenos AI – Digital Financial Advice: Identify customers who are unlikely to be able to continue without finding a new source of income, hence both reducing risk and offering the opportunity to provide suitable financial solutions to them.
– Ends –
About Temenos
Temenos AG (SIX: TEMN) is the world’s leader in banking software. Over 3,000 banks across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 500 million banking customers. Temenos offers cloud-native, cloud-agnostic and AI-driven front office, core banking, payments and fund administration software enabling banks to deliver frictionless, omnichannel customer experiences and gain operational excellence.
Temenos software is proven to enable its top-performing clients to achieve cost-income ratios of 26.8% half the industry average and returns on equity of 29%, three times the industry average. These clients also invest 51% of their IT budget on growth and innovation versus maintenance, which is double the industry average, proving the banks’ IT investment is adding tangible value to their business.
For more information, please visit www.temenos.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200422005802/en/
Contact information
Jessica Wolfe & Grace Collins
Temenos Global Public Relations
Tel: +1 610 232 2793 & + 44 20 7423 3969
Email : press@temenos.com
Alistair Kellie & Andrew Adie
Newgate Communications on behalf of Temenos
Tel: +44 20 7680 6550
Email: allnewgatetemenos@newgatecomms.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
